Free Trial

Cabaletta Bio (CABA) Competitors

Cabaletta Bio logo
$2.90 +0.01 (+0.35%)
Closing price 04:00 PM Eastern
Extended Trading
$2.90 0.00 (-0.17%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CABA vs. ANAB, VALN, PHAT, PROK, KURA, AVBP, PVLA, MRVI, CRMD, and ABUS

Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include AnaptysBio (ANAB), Valneva (VALN), Phathom Pharmaceuticals (PHAT), ProKidney (PROK), Kura Oncology (KURA), ArriVent BioPharma (AVBP), Palvella Therapeutics (PVLA), Maravai LifeSciences (MRVI), CorMedix (CRMD), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

Cabaletta Bio vs. Its Competitors

AnaptysBio (NASDAQ:ANAB) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Cabaletta Bio has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$91.28M10.52-$145.23M-$4.48-7.65
Cabaletta BioN/AN/A-$115.86M-$2.71-1.07

AnaptysBio currently has a consensus price target of $54.78, suggesting a potential upside of 59.75%. Cabaletta Bio has a consensus price target of $13.44, suggesting a potential upside of 363.60%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than AnaptysBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AnaptysBio
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.67
Cabaletta Bio
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

Cabaletta Bio has a net margin of 0.00% compared to AnaptysBio's net margin of -107.66%. Cabaletta Bio's return on equity of -92.11% beat AnaptysBio's return on equity.

Company Net Margins Return on Equity Return on Assets
AnaptysBio-107.66% -366.98% -30.58%
Cabaletta Bio N/A -92.11%-74.08%

AnaptysBio has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500.

In the previous week, AnaptysBio had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 16 mentions for AnaptysBio and 15 mentions for Cabaletta Bio. AnaptysBio's average media sentiment score of 0.52 beat Cabaletta Bio's score of 0.49 indicating that AnaptysBio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AnaptysBio
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Cabaletta Bio
1 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Cabaletta Bio beats AnaptysBio on 9 of the 13 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CABA vs. The Competition

MetricCabaletta BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$265.23M$3.40B$6.04B$10.51B
Dividend YieldN/A2.30%5.73%4.80%
P/E Ratio-1.0722.9285.4427.36
Price / SalesN/A268.92515.69196.40
Price / CashN/A46.9537.5761.53
Price / Book0.9310.5512.426.82
Net Income-$115.86M-$52.58M$3.32B$276.89M
7 Day Performance20.33%1.09%1.01%0.27%
1 Month Performance51.83%16.09%10.75%8.31%
1 Year Performance-33.03%18.41%76.20%35.60%

Cabaletta Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CABA
Cabaletta Bio
2.9994 of 5 stars
$2.90
+0.3%
$13.44
+363.6%
-32.0%$265.23MN/A-1.0750High Trading Volume
ANAB
AnaptysBio
2.6382 of 5 stars
$32.46
+3.5%
$52.00
+60.2%
-8.3%$908.78M$123.16M-7.25100Analyst Forecast
VALN
Valneva
2.175 of 5 stars
$10.50
+1.3%
$15.00
+42.9%
+84.2%$902.27M$183.52M-10.71700
PHAT
Phathom Pharmaceuticals
2.3992 of 5 stars
$12.53
+6.0%
$17.50
+39.7%
-18.2%$888.93M$114.04M-2.65110
PROK
ProKidney
2.6524 of 5 stars
$2.99
-1.0%
$6.25
+109.0%
+76.6%$879.90M$80K-5.253
KURA
Kura Oncology
4.012 of 5 stars
$9.93
+0.8%
$24.10
+142.7%
-46.7%$861.89M$83.28M-4.39130
AVBP
ArriVent BioPharma
2.0781 of 5 stars
$20.90
+0.2%
$39.14
+87.3%
-28.4%$847.91MN/A-5.2040Analyst Downgrade
PVLA
Palvella Therapeutics
2.0223 of 5 stars
$76.22
+9.0%
$75.50
-0.9%
N/A$842.99M$42.81M-6.30N/A
MRVI
Maravai LifeSciences
3.3314 of 5 stars
$3.30
+3.4%
$5.22
+58.1%
-60.9%$842.70M$219.83M-2.43610Analyst Forecast
CRMD
CorMedix
2.8421 of 5 stars
$10.58
-1.4%
$18.00
+70.1%
+4.8%$825.88M$43.47M14.1130
ABUS
Arbutus Biopharma
1.2616 of 5 stars
$4.28
+4.1%
$5.00
+16.8%
+9.8%$820.47M$15.42M-14.7690

Related Companies and Tools


This page (NASDAQ:CABA) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners